These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7867311)

  • 21. Comparative in vitro activity of lomefloxacin (SC 47111 or NY-198) against fresh clinical bacterial isolates.
    Wright DN; Saxon B; Matsen JM
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):7S-11S. PubMed ID: 2791501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of lomefloxacin (SC 47111 or NY-198), a new quinolone antimicrobial, against clinical isolates of common pathogens.
    Sonstein SA; Dahlgren J
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):21S-28S. PubMed ID: 2791494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G; Prosser BL
    Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens.
    Felmingham D; Robbins MJ
    Diagn Microbiol Infect Dis; 1992; 15(4):339-43. PubMed ID: 1319301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of lomefloxacin (NY-198 or SC 47111).
    Shah PM; Müller S; Kipp J; Stille W
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):97S-101S. PubMed ID: 2791506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lomefloxacin (SC-47111 or NY-198). Comparative antimicrobial activity against 2002 clinical isolates from hospitals in Mexico City.
    Durazo F; Resano F; Gonzalez MA
    Diagn Microbiol Infect Dis; 1990; 13(1):71-5. PubMed ID: 2331854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of lomefloxacin against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum.
    Hoban D; DeGagne P; Witwicki E
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):83S-86S. PubMed ID: 2507222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone.
    Molinari G; Bandelloni R; Paglia P; Debbia E; Schito GC
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):53S-56S. PubMed ID: 2791499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.
    Edwards R; Kanematsu M; Greenwood D
    J Antimicrob Chemother; 1988 Dec; 22(6):885-90. PubMed ID: 3243736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens.
    Debbia EA; Pesce A; Schito GC
    Am J Med; 1992 Apr; 92(4A):45S-47S. PubMed ID: 1316070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial and plasmid curing activity of lomefloxacin in vitro.
    Derlot E; Poyart-Salmeron C; Courvalin P
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1048-52. PubMed ID: 2515963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1,500 clinical isolates.
    Cormican MG; Erwin MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Mar; 24(3):169-72. PubMed ID: 8724404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
    DiVincenzo CA; Shatzer KL; Venezio FR
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):13S-16S. PubMed ID: 2507220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.
    Lefèvre JC; Bauriaud R; Gaubert E; Escaffre MC; Lareng MB
    Chemotherapy; 1992; 38(5):303-7. PubMed ID: 1337506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of lomefloxacin as compared with ciprofloxacin.
    Inderlied CB; Lancero MG; Bermudez LM; Young LS
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):17S-20S. PubMed ID: 2791493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activity of lomefloxacin.
    Leigh DA; Tait S; Walsh B
    J Antimicrob Chemother; 1991 May; 27(5):589-98. PubMed ID: 1885417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial effects of lomefloxacin in vitro.
    Chambers ST; Peddie BA; Robson RA; Begg EJ; Boswell DR
    J Antimicrob Chemother; 1991 Apr; 27(4):481-9. PubMed ID: 1856127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter comparative study of the in vitro activity of fleroxacin and other antimicrobial agents.
    Markowitz SM; Williams DS; Hanna CB; Parker JL; Pierce MA; Steele JC
    Chemotherapy; 1995; 41(6):477-86. PubMed ID: 8529440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.